All articles tagged with #insmed
Insmed's Phase 2b trial of brensocatib in CRSsNP did not meet efficacy endpoints, leading to discontinuation of that program, but the company acquired a promising monoclonal antibody, INS1148, for respiratory and inflammatory diseases, expanding its pipeline.
Insmed received FDA approval for its lung disease drug brensocatib, marketed as Brinsupri for bronchiectasis, with potential peak sales of $5 billion, positioning it as a major growth driver for the company, which is also seeking approvals in Europe, the U.K., and Japan.
Insmed is considered an attractive investment opportunity but is currently expensive, while Regeneron faces ongoing troubles, raising questions about its future prospects in biotech.
Insmed's experimental therapy for pulmonary arterial hypertension succeeded in a mid-stage trial, causing shares of competitors Liquidia and United Therapeutics to fall in premarket trading.
Stock futures are slightly higher amid ongoing US-China trade talks, with notable movements in Tesla, TSMC, McDonald's, Smucker, Casey's, Insmed, and GameStop, driven by earnings reports, company news, and analyst ratings.
Insmed Incorporated's stock surged by up to 110% following positive study results for a drug treating bronchiectasis, a chronic lung condition. Analysts are optimistic about the company's future, with plans to file for U.S. market clearance and potential applications for other diseases.
Insmed's stock surged 135% after announcing successful Phase 3 trial results for brensocatib in treating non-cystic fibrosis bronchiectasis, showing significant reductions in pulmonary exacerbations. The company plans to file for FDA approval in late 2024, with potential U.S. launch in mid-2025 and subsequent launches in Europe and Japan.
Insmed's experimental drug brensocatib successfully reduced lung problems in bronchiectasis patients during a Phase 3 trial, leading to a significant increase in the company's share price. Both tested dosages of the drug met the primary endpoint by reducing pulmonary exacerbations by about 20% compared to placebo, with analysts predicting potential billion-dollar annual sales if approved.